InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Discover the full record of transactions filed by Laporte Kathleen. Director active across 3 companies, notably 89bio, Inc.. Aggregated, 10 reports have been published. Breakdown: 0 buy · 2 sells. Total volume traded: €314k. History available since 17 July 2023. The latest transaction was disclosed on 15 January 2026 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
10 of 10 declarations
LAPORTE KATHLEEN is a Director of Precipio, Inc., CERO THERAPEUTICS HOLDINGS, INC., and 89bio, Inc. Across 7 filings in total, the sampled recent filings run from 2023-07-18 to 2025-04-17, with EUR 0 of purchases and EUR 209119 of sales, and the transaction nature shown is Attribution.